We use cookies to understand how visitors search for and consume the information we provide, so that we can improve their experience. By browsing this website, you indicate your acceptance of the use of such cookies
Accept
Read more
Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Our products
& pipeline
Diseases we target
GS010 for LHON
GS030 for Retinitis Pigmentosa
GS030 for Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Investors
& media
Company Overview
Press releases
Events & presentations
Stock information
Governance
Documentation
Events & presentations
Year
All
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
Company and personnel
GS010
GS030
Technologies
Other
09 Apr 2013
April 9, 2013: GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic GeneTherapy.
View previous 9 articles
1
…
4
5
6
7
8
9
Stay informed
Subscribe to the newsletter to get the latest GenSight Biologics news
Fields marked with an
*
are required
Email Address
*
Your interest
Please select
LHON
Retinitis pigmentosa
GA in Wet-AMD
Any company-related news
You are
Please select
Patient or caregiver
Healthcare professional
Other
Go back to the page of the page
